Effects of lycopene on the Insulin-like growth factor (IGF) system in premenopausal breast cancer survivors and women at high familial breast cancer risk.
Insulin-like growth factor-I (IGF-I) is an important growth factor associated with increased risk of premenopausal breast cancer. We conducted a randomized, placebo-controlled, double-blind, crossover trial to evaluate whether tomato-derived lycopene supplementation (30 mg/day for 2 mo) decreases se...
| Published in: | Nutrition & Cancer Vol. 60; no. 3; pp. 342 - 354 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | research tables/charts Journal Article |
| Published: |
Taylor & Francis Ltd
2008
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105771811&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 105771811 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 01635581 7MS jtl: Nutrition & Cancer issn: 01635581 maglogo: N pubinfo: dt: 2008 vid: 60 iid: 3 pid: 377 pub: Taylor & Francis Ltd place: Philadelphia, Pennsylvania artinfo: ui: 105771811 105771811 2009939282 10.1080/01635580701861777 NLM18444168 105771811 ppf: 342 ppct: 12 formats: fmt: @attributes: type: P tig: atl: Effects of lycopene on the Insulin-like growth factor (IGF) system in premenopausal breast cancer survivors and women at high familial breast cancer risk. aug: au: Voskuil DW Vrieling A Korse CM Beijnen JH Bonfrer JMG van Doorn J Kaas R Oldenburg HSA Russell NS Rutgers EJT Verhoef S van Leeuwen FE van't Veer LJ Rookus MA affil: Division of Experimental Therapy and the Department of Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. sug: subj: Breast Neoplasms Familial and Genetic Breast Neoplasms Risk Factors Lycopene Blood Premenopause Physiology Somatomedins Funding Source Nutrition Human ab: Insulin-like growth factor-I (IGF-I) is an important growth factor associated with increased risk of premenopausal breast cancer. We conducted a randomized, placebo-controlled, double-blind, crossover trial to evaluate whether tomato-derived lycopene supplementation (30 mg/day for 2 mo) decreases serum levels of total IGF-I in premenopausal women with 1) a history of breast cancer (n = 24) or 2) a high familial breast cancer risk (n = 36). Also, IGF binding protein (IGFBP) increasing effects were evaluated. Lycopene supplementation did not significantly alter serum total IGF-I and other IGF system components in the 2 study populations combined. However, statistically significant discordant results were observed between the 2 study populations (i.e., P < 0.05 for total IGF-I, free IGF-I, and IGFBP-3). Total IGF-I and IGFBP-3 were increased in the breast cancer survivor population [total IGF-I = 7.0%, 95% confidence interval (CI) = -0.2 to 14.3%; IGFBP-3 = 3.3%, 95% CI = 0.7-6.0%), and free IGF-I was decreased in the family history population (-7.6%, 95% CI = -14.6 to -0.6%). This randomized controlled trial shows that 2 mo of lycopene supplementation has no effect on serum total IGF-I in the overall study population. However, lycopene effects were discordant between the 2 study populations showing beneficial effects in high-risk healthy women but not in breast cancer survivors. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|